In an exciting development for the biotech industry, Leads Biolabs has successfully raised $189,000,000 to support groundbreaking research and development initiatives at Abivax, a clinical-stage biotechnology company dedicated to harnessing the body’s natural regulatory mechanisms to stabilize immune responses in patients with chronic inflammatory diseases. This substantial funding infusion will accelerate Abivax’s mission to bring innovative therapeutics to market, specifically by advancing the clinical development of their lead drug candidate, obefazimod. Currently evaluated in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis, obefazimod represents a novel, orally administered, once-daily therapy. It is the first and only molecule designed to enhance the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response, offering new hope for patients suffering from inflammatory bowel diseases.
The fresh capital will not only bolster the ongoing Phase 3 trials for ulcerative colitis but also pave the way for a Phase 2a clinical trial aimed at assessing the efficacy of obefazimod in patients with Crohn’s disease. This exciting dual-path approach, underpinned by a robust foundation of scientific innovation, has the potential to carve out a new therapeutic class, often referred to as miR-124 enhancers. The investment highlights Leads Biolabs’ strong confidence in Abivax’s unique scientific approach and its promise to deliver differentiated treatment options for challenging and chronic inflammatory conditions. With this new funding, Abivax is well-positioned to further its research initiatives, drive regulatory advancements, and ultimately transform the landscape of treatment for patients battling these debilitating diseases.
